INVESTIGADORES
DAMIANI Armando Mario
artículos
Título:
Serological responses and clinical outcome after vaccination of mares and foals with equine herpesvirus type 1 and 4 (EHV-1 and EHV-4) vaccines
Autor/es:
BRESGEN C, LÄMMER M, WAGNER B, OSTERRIEDER N, DAMIANI AM
Revista:
VETERINARY MICROBIOLOGY
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Lugar: Amsterdam; Año: 2012 vol. 160 p. 9 - 16
ISSN:
0378-1135
Resumen:
Equine herpesvirus type 1 and type 4 (EHV-1 and EHV-4) cause infections of horses
worldwide. While both EHV-1 and EHV-4 cause respiratory disease, abortion and
myeloencephalopathy are observed after infection with EHV-1 in the vast majority of
cases. Disease control is achieved by hygiene measures that include immunization with
either inactivated or modified live virus (MLV) vaccine preparations. We here compared
the efficacy of commercially available vaccines, an EHV-1/EHV-4 inactivated combination
and an MLV vaccine, with respect to induction of humoral responses and protection of
clinical disease (abortion) in pregnant mares and foals on a large stud with a total of
approximately 3500 horses. The MLV vaccine was administered twice during pregnancy
(months 5 and 8 of gestation) to 383 mares (49.4%), while the inactivated vaccine was
administered three times (months 5, 7, and 9) to 392 mares (50.6%). From the vaccinated
mares, 192 (MLV) and 150 (inactivated) were randomly selected for serological analyses.
There was no significant difference between the groups with respect to magnitude or
duration of the humoral responses as assessed by serum neutralization assays (median
range from 1:42 to 1:130) and probing for EHV-1-specific IgG isotypes, although
neutralizing responses were higher in animals vaccinated with the MLV preparation at all
time points sampled. The total number of abortions in the study population was 55/775
(7.1%), 9 of which were attributed to EHV-1. Seven of the abortions were in the inactivated
and two in the MLV vaccine group (p = 0.16). When foals of vaccinated mares were
followed up, a dramatic drop of serum neutralizing titers (median below 1:8) was
observed in all groups, indicating that the half-life of maternally derived antibody is less
than 4 weeks.